Sponsor or institution

Clinical trials and research at Marker Therapeutics, INC.

• 2Clinical trials
• 10NIH research projects
• 1Country

All recruiting trials (2)

• MT-401-OTS treatment for relapsed AML or high‑risk MDS (safety focus)

  This trial will test whether escalating doses of an experimental off‑the‑shelf cell therapy called MT-401-OTS are safe and can reduce residual disease in adults aged 65 and older with relapsed or persistent AML or high‑risk MDS with low blast counts.

  Recruiting at 3 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 2 other locations · NCT06552416

• Evaluating MT-601 for patients with relapsed or refractory lymphoma

  This study is testing a new treatment called MT-601 to see if it can help people with relapsed or hard-to-treat lymphoma feel better.

  Recruiting at 7 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 6 other locations · NCT05798897

NIH-funded research (10)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Multi-tumor antigen T cell therapy for pancreatic cancer

  A patient-facing overview of a new autologous T cell therapy aimed at pancreatic cancer that expresses several tumor markers to help fight the disease.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11444174

• Multi-antigen T cell therapy for relapsed NHL

  A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11374461

• Donor-derived multi-antigen T-cell therapy after hypomethylating bridging for relapsed AML post-transplant

  A donor-derived T-cell treatment given after hypomethylating drugs for people whose AML has returned after a stem cell transplant.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11181329

• Personalized multi‑antigen T‑cell therapy for metastatic pancreatic cancer after FOLFIRINOX

  Patients with metastatic pancreatic cancer who have completed FOLFIRINOX receive a personalized T‑cell treatment made from their own blood that targets several tumor proteins to help the immune system attack the cancer.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11180449

• MT-601 T Cell Therapy for Relapsed Non-Hodgkin Lymphoma

  This opportunity explores a new T cell therapy called MT-601 for people with Non-Hodgkin Lymphoma that has returned after previous treatments.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11164733

• Improving T cell therapy for pancreatic cancer

  This study is testing a new way to make T cell therapy work better for people with pancreatic cancer by using a special protein to help the immune cells grow and fight the cancer more effectively, while keeping patients safe.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11116994

• A new T-cell treatment for acute myeloid leukemia after transplant

  This project explores a new T-cell treatment designed to prevent acute myeloid leukemia from returning in people who have had a stem cell transplant.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11042150

• Using patient-derived T cells to target pancreatic cancer after chemotherapy

  This study is testing a new treatment called MT-601, which uses specially modified T cells from your own blood to help fight metastatic pancreatic cancer after you've had FOLFIRINOX chemotherapy, with the hope of improving how well your body can target and control the cancer.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11006021

• New T cell therapy for patients with relapsed Non-Hodgkin Lymphoma

  This study is testing a new treatment for people with relapsed Non-Hodgkin Lymphoma that uses their own immune cells to better fight cancer by targeting multiple markers on the cancer cells, with the hope of making the treatment more effective and lowering the risk of the cancer coming back.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-10922163

• New T cell therapy for patients with relapsed acute myeloid leukemia after stem cell transplant

  This study is testing a new T cell therapy called MT-401 for patients with relapsed acute myeloid leukemia (AML) who have had a stem cell transplant, to see if it can better target cancer cells while protecting healthy ones.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-10901992

Quick answers

How many clinical trials run by Marker Therapeutics, INC. are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →